We are live on ! Find out more
ACIU icon

AC Immune

35 hedge funds and large institutions have $49.8M invested in AC Immune in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

3% less funds holding

Funds holding: 3635 (-1)

3.15% less ownership

Funds ownership: 19.67%16.52% (-3.2%)

11% less call options, than puts

Call options by funds: $105K | Put options by funds: $118K

13% less capital invested

Capital invested by funds: $57.2M → $49.8M (-$7.35M)

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
6
Reduced
12
Closed
5
Calls
$105K
Puts
$118K
Net Calls
-$13K
Net Calls Change
-$516K

ACIU Hedge Fund Activity: Q2 2022 in Review

35 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q2 2022, worth a combined $49.8M — down 13% from $57.2M a quarter earlier.

Fund positioning in ACIU was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $294K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $1.94M sold.

  • 35 institutional investors held AC Immune (ACIU) as of Q2 2022, down from 36 in Q1 2022.
  • Funds reported $49.8M of AC Immune stock for Q2 2022, down 13% quarter-over-quarter.
  • 5 funds opened new AC Immune positions in Q2 2022 and 5 closed out, a net change of 0 holders.
  • The largest AC Immune buyer in Q2 2022 was BlackRock, an estimated $294K added.
  • The largest AC Immune seller in Q2 2022 was EcoR1 Capital, an estimated $1.94M sold.

Based on aggregated 13F filings for Q2 2022.